Garvagliptin
Garvagliptin (ZYDPLA1) is an orally active, competitive and long acting DPP4 Inhibitor, with an IC50 of 2.99 nM against human recombinant DPP IV. Garvagliptin (ZYDPLA1) exhibits antihyperglycemic effect[1].
Product Specifications
CAS Number
1601479-87-1
Product Name Alternative
ZYDPLA1
UNSPSC
12352005
Target
Dipeptidyl Peptidase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/garvagliptin.html
Smiles
CS(=O)(N1CC2=C(C1)CN([C@@H]3C[C@@H]([C@@H](C4=C(C=CC(F)=C4)F)OC3)N)C2)=O
Molecular Formula
C18H23F2N3O3S
Molecular Weight
399.46
References & Citations
[1]Poonam Giri, Sensitive and specific LC-ESI-MS/MS method for determination of ZYDPLA1, a novel long-acting dipeptidyl peptidase 4 inhibitor in rat plasma: An application for toxicokinetic study in rats. Biomed Chromatogr. 2017 Nov;31 (11) .|[2]Mason, V.L., et al. 16th International Congress of Endocrinology/96th Annual Meeting and Exposition of the Endocrine Society (ICE/ENDO), Chicago, Illinois, USA-June 21-24, 2014. Drugs of the Future v. 39, n. 9 (2014) : 0661.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC041174-500 1x 500 µL
PTH / Parathyroid Hormone (N-Terminal) (PTH/1174), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 